Background: Epidermodysplasia verruciformis (EV) is a rare autosomal-recessive disorder characterized by widespread and persistent infection with human papilloma virus (HPV) and a risk of malignant degeneration. Most cases of EV are caused by mutations in the two EV genes, EVER1/TMC6 and EVER2/TMC8. The clinical presentation of EV takes two different forms, which coexist in most cases. Over a period of years, patients develop plane warts and pityriasis versicolor-like lesions. Sixteen cases of EV in HIV-positive patients have been clinically investigated and reported in the literature. However, different inherited susceptibilities towards HPV infection in immunodeficient patients, like HIV-positive patients, have only rarely been addressed. Observation: We describe a 22-year-old female patient with a congenital HIV infection, who presented with slowly progressing and confluent erythematous papules on her hands and hypopigmented macules on her extremities. The histopathology was typical for EV, and HPV5 was detected by PCR and reverse hybridization. The 44-year-old HIV-positive mother has no typical EV lesions. The patient is homozygous for an A to T single nucleotide polymorphism (SNP) at position 917 of the TMC8/EVER2 gene. The mother of the patient is heterozygous for this SNP. Conclusion: These results support the hypothesis that the combination of immunodeficiency and a susceptibility allele may contribute to the differences in occurrence of EV in HIV-positive patients.

1.
Häusermann P, Lutter S, Meigel W, Rufli T: Das Lewandowsky-Lutz-Syndrom: Die Erstbeschreibung und drei weitere Basler Fälle der Epidermodysplasia verruciformis. Z Hautkr 2002;77:176–180.
2.
Majewski S, Jablonska S: Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995;131:1312–1318.
3.
De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004;324:17–27.
4.
Orth G: Genetics of epidermodysplasia verruciformis: insights into host defence against papillomaviruses. Semin Immunol 2006;18:362–374.
5.
Lutzner MA: Epidermodysplasia verruciformis. An autosomal recessive disease characterised by viral warts and skin cancer: a model for viral oncogenesis. Bull Cancer 1978;65:169–182.
6.
Harris AJ, Purdie K, Leigh IM, Proby C, Burge S: A novel human papillomavirus identified in epidermodysplasia verruciformis. Br J Dermatol 1997;136:587–591.
7.
Androphy EJ, Dvoretzky I, Lowy DR: X-linked inheritance of epidermodysplasia verruciformis: genetic and virologic studies of a kindred. Arch Dermatol 1985;121:864–868.
8.
Zavattaro E, Azzimonti B, Mondini M, De Andrea M, Borgogna C, Dell’Oste V, Ferretti M, Nicola S, Cappellano G, Carando A, Leigheb G, Landolfo S, Dianzani U, Gariglio M: Identification of defective Fas function and variation of the perforin gene in an epidermodysplasia verruciformis patient lacking EVER1 and EVER2 mutations. J Invest Dermatol 2007;25:732–735.
9.
Akgül B, Köse O, Safali M, Purdie K, Cerio R, Proby C, Storey A: A distinct variant of epidermodysplasia verruciformis in a Turkish family lacking EVER1 and EVER2 mutations. J Dermatol Sci 2007;46:214–216.
10.
Hultgren TL, Srinivasan SK, DiMaio DJ: Epidermodysplasia verruciformis occurring in a patient with human immunodeficiency virus: a case report. Cutis 2007;79:307–311.
11.
Mermet I, Guerrini JS, Cairey-Remonnay S, Drobacheff C, Faivre B, Gaillard M, Kantelip B, Pretet JL, Riethmuller D, Aubin F: Cervical intraepithelial neoplasia associated with epidermodysplasia verruciformis HPV in an HIV-infected patient: a manifestation of immune restoration syndrome. Eur J Dermatol 2007;17:149–152.
12.
Hu W, Nuovo G, Willen M, Somach S: Epidermodysplasia verruciformis in two half brothers with HIV infection. J Cutan Med Surg 2004;8:357–360.
13.
Davison SC, Francis N, McLean K, Bunker CB: Epidermodysplasia verruciformis-like eruption associated with HIV infection. Clin Exp Dermatol 2004;29:311–312.
14.
Carré D, Dompmartin A, Verdon R, Comoz F, Le Brun E, Freymuth F, Leroy D: Epidermodysplasia verruciformis in a patient with HIV infection: no response to highly active antiretroviral therapy. Int J Dermatol 2003;42:296–300.
15.
Trauner MA, Ruben BS, Hatcher SL, Lawry MA: Groin eruption in an HIV-positive man: epidermodysplasia verruciformis (EDV). Arch Dermatol 2002;138:527–532.
16.
Haas N, Fuchs PG, Hermes B, Henz BM: Remission of epidermodysplasia verruciformis-like skin eruption after highly active antiretroviral therapy in a human immunodeficiency virus-positive patient. Br J Dermatol 2001;145:669–670.
17.
Barzegar C, Paul C, Saiag P, Cassenot P, Bachelez H, Autran B, Gorochov G, Petit A, Dubertret L: Epidermodysplasia verruciformis-like eruption complicating human immunodeficiency virus infection. Br J Dermatol 1998;139:122–127.
18.
Berger TG, Sawchuk WS, Leonardi C, Langenberg A, Tappero J, Leboit PE: Epidermodysplasia verruciformis-associated papillomavirus infection complicating human immunodeficiency virus disease. Br J Dermatol 1991;124:79–83.
19.
Prose NS, von Knebel-Doeberitz C, Miller S, Milburn PB, Heilman E: Widespread flat warts associated with human papillomavirus type 5: a cutaneous manifestation of human immunodeficiency virus infection. J Am Acad Dermatol 1990;23:978–981.
20.
Grimm I: Cryptococcosis and torulopsidosis of the skin and lung and epidermodysplasia verruciformis in AIDS (acquired immune deficiency syndrom). Hautarzt 1984;35:653–655.
21.
Barr BB, Benton EC, McLaren K, Bunney MH, Smith IW, Blessing K, Hunter JA: Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989;334:224–225.
22.
Gross G, Ellinger K, Roussaki A, Fuchs PG, Peter HH, Pfister H: Epidermodysplasia verruciformis in a patient with Hodgkin’s disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol 1988;91:43–48.
23.
Tanigaki T, Kanda R, Sato K: Epidermodysplasia verruciformis (L-L, 1922) in a patient with systemic lupus erythematosus. Arch Dermatol Res 1986;278:247–248.
24.
Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, Proby CM: Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289–297.
25.
de Koning M, Quint W, Struijk L, Kleter B, Wanningen P, van Doorn LJ, Weissenborn SJ, Feltkamp M, ter Schegget J: Evaluation of a novel highly sensitive, broad-spectrum PCR-reverse hybridization assay for detection and identification of beta-papillomavirus DNA. J Clin Microbiol 2006;44:1792–1800.
26.
Resnick RM, Cornelissen MT, Wright DK, Eichinger GH, Fox HS, ter Schegget J, Manos MM: Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990;82:1477–1484.
27.
Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M: Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002;32:579–581.
28.
Gober MD, Rady PL, He Q, Tucker SB, Tyring SK, Gaspari AA: Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol 2007;127:817–820.
29.
Patel AS, Karagas MR, Pawlita M, Waterboer T, Nelson HH: Cutaneous human papillomavirus infection, the EVER2 gene and incidence of squamous cell carcinoma: a case-control study. Int J Cancer 2008;122:2377–2379.
31.
Bochud PY, Hersberger M, Taffé P, Bachud M, Stein C, Rodrigues S, Calandra T, Francioli P, Telenti A, Speck R, Aderem A, Swiss HIV Cohort Study: Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007;21:441–446.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.